Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. (19th August 2022)

• Record Type: Journal Article
• Authors: Alosaimy, Sara; Lagnf, Abdalhamid M; Hobbs, Athena L V; Mubarez, Musa; Kufel, Wesley D; Morrisette, Taylor; Polisetty, Radhika S; Li, David; Veve, Michael P; Simon, Sam P; Truong, James; Finch, Natalie; Venugopalan, Veena; Rico, Matthew; Amaya, Lee; Yost, Christine; Cubillos, Ashley; Chandler, Elisabeth; Patch, Megan; Smith, Ian Murphy Kelsey; Biagi, Mark; Wrin, Justin; Moore, W Justin; Molina, Kyle C; Rebold, Nicholas; Holger, Dana; Kunz Coyne, Ashlan J; Jorgensen, Sarah C J; Witucki, Paige; Tran, Nikki N; Davis, Susan L; Sakoulas, George; Rybak, Michael J;
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e1444
• Page End: e1455
• Publication Date: 2022-08-19
• Subjects: vancomycin -- ceftolozane-tazobactam -- piperacillin-tazobactam -- nephrotoxicity; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac670
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T). Our aim was to investigate the AKI incidence of VAN in combination with C/T (VAN/C/T) compared with VAN in combination to TZP (VAN-TZP). Methods: We conducted a multicenter, observational, comparative study across the United States. The primary analysis was a composite outcome of AKI and risk, injury, failure, loss, end stage renal disease; Acute Kidney Injury Network; or VAN-induced nephrotoxicity according to the consensus guidelines. Multivariable logistic regression analysis was conducted to adjust for confounding variables and stratified Kaplan–Meir analysis to assess the time to nephrotoxicity between the 2 groups. Results: We included VAN/C/T (n = 90) and VAN-TZP (n = 284) at an enrollment ratio of 3:1. The primary outcome occurred in 12.2% vs 25.0% in the VAN-C/T and VAN-TZP groups, respectively ( P = .011). After adjusting for confounding variables, VAN-TZP was associated with increased odds of AKI compared with VAN-C/T; with an adjusted odds ratio of 3.308 (95% confidence interval, 1.560–6.993). Results of the stratified Kaplan–Meir analysis with log-rank time-to-nephrotoxicity analysis indicate that time to AKI was significantly shorter among patients who received VAN-TZP ( P = .004). Cox proportional hazards analysis demonstrated that TZP was consistent with the primary analysis ( P = .001). Conclusions: Collectively, our results suggest that the AKI is not likely to be related to tazobactam but rather to piperacillin, which is a component in VAN-TZP but not in VAN-C/T. Abstract : Vancomycin in combination with piperacillin-tazobactam was associated with increased odds of acute kidney injury compared with vancomycin in combination with ceftolozane-tazobactam, with an adjusted odds ratio of 3.308 after adjusting for confounding variables in a multivariable logistic regression model.